Glaxo Ventolin HFA phase-in
Non-chlorofluorocarbon albuterol inhaler Ventolin HFA will gradually replace existing CFC product following launch, GlaxoSmithKline says. Company is meeting with physicians and patients to determine the best way to implement the CFC phase-out. Ventolin HFA was approved April 12 (1"The Pink Sheet" April 23, p. 34)
You may also be interested in...
GlaxoSmithKline Ventolin HFA labeling states that switching to the non-chlorofluorocarbon inhaler from a CFC-propelled product does not result in "any clinically significant changes in the efficacy profile."
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials